Today's 'Trump Trade' Has a Catchy Nickname. But Should You Buy It?
The upshot, for some, is the belief that Trump eventually delays or otherwise modifies policies the market doesn't like, so trade-policy negativity will be shaken off before long.
There's a nickname for this: the "TACO Trade." But investors have mixed opinions about whether it's a safe bet.The 'Trump Trade' has evolved. How investors should play it is up for debate.
The early days of President Donald Trump's second administration supercharged a climb in stocks that started late last summer, lifting the major indexes and some specific assets—shares of Tesla (TSLA), cryptocurrency—in particular. Sprinkled in was volatility around stock and sectors seen as likely to be helped or hurt by spending and regulatory efforts.
Some of that remains in place, but the action these days is largely around global trade policy. Investors are attempting to figure out from day to day what the next twist in Trump's tariff strategy could be and how it might affect stocks in the hours, days and weeks ahead.
That's taken on particular salience since stocks swooned after the April 2 'Liberation Day' tariff announcements and then began working their way back. The upshot, for some, is the belief that Trump eventually delays or otherwise modifies policies the market doesn't like, so trade-policy negativity will be shaken off before long.
There's an alliterative nickname for this: the 'TACO Trade,' short for 'Trump Always Chickens Out,' coined last month by a Financial Times columnist. (Asked about it at a press conference, Trump was unamused.) Discussion of the term has taken on a political character and become fodder for The Wall Street Journal, The New York Times, and other publications—now including this one—but it has also found its way to the lips of investors and analysts.
BCA Research mentioned it in a note earlier this week, calling the trade 'overcooked' and suggesting that investors may have grown too sanguine. 'Risk assets price in trade deals and de-escalation along with limited policy damage despite ongoing volatility,' they wrote. Pepperstone analyst Michael Brown in late May effectively equated taco trading with buying the dip.
Deutsche Bank analysts in their own note this week didn't use the taco term, but—in raising their year-end target for the S&P 500—cited the idea that 'the administration had already relented, driven primarily by the market reaction, and before the emergence of significant economic or political pain. This reinforces the view that if negative impacts of tariffs do materialize, we will get further relents.'
Other factors have undoubtedly aided stocks in recent weeks even as questions about the path forward for trade and the economy remain. The first-quarter earnings season was generally seen as strong, and Nvidia's (NVDA) results and outlook have supported the AI trade. Futures markets indicate an expectation that the Federal Reserve cuts rates twice by the end of the year, as the job market shows signs of weakness and inflation approaches the Fed's target.
JP Morgan analysts on Tuesday shared a calendar of key trade dates in the coming months, noting a litany of summits and policy expirations—a 90-day pause on tariffs against the EU expires next month, and reduced U.S.-China tariffs are set to pass in August—between now and the end of the year. The administration reportedly asked countries to submit their 'best offers' in trade negotiations by Wednesday.
Some investors don't buy the inevitability of bullishness around trade news. 'We think that, unfortunately, as the so-called 'TACO Trade' becomes more viral, it becomes more likely that Trump will stick to higher tariffs just to prove a point,' Panmure Liberum Head of Strategy Joachim Klement recently told a Reuters interviewer.
In short, it may not pay to oversimplify the effect that trade could have on markets in the coming months. 'There are no signs of a summer break from tariff drama,' JP Morgan wrote.
Read the original article on Investopedia
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Ukraine needs long-term security guarantees, Taoiseach says
International borders must not be changed by force, the Taoiseach has said, ahead of a meeting between the presidents of the United States and Ukraine. Micheal Martin attended a virtual leaders' meeting of the so-called 'coalition of the willing' in support of Ukraine on Sunday. The call was convened by Sir Keir Starmer, French President Emmanuel Macron and German Chancellor Friedrich Merz. On Monday, Volodymyr Zelensky is meeting Donald Trump with several EU leaders, including Sir Keir, also travelling to Washington DC in a show of solidarity with the Ukrainian president. Mr Martin, who will not be in Washington, said he had assured Mr Zelensky on Sunday that Ireland will 'continue to steadfastly support Ukraine'. EU leaders have agreed that sanctions and wider economic measures 'will be reinforced' if Russia continues its military action. The Taoiseach also said that he believes Ukraine needs 'long-term security guarantees'. Speaking after Sunday's online conference, Mr Martin said: 'I welcomed the opportunity to join other European leaders today to discuss developments on ending the war in Ukraine. 'We had a very useful engagement with President Zelensky as he prepares to meet with President Trump tomorrow in Washington. 'I welcome the initiative by President Trump to seek the ending of the Russian war of aggression against Ukraine. Ireland, together with our European partners, continues to contribute to these efforts to achieve a just and lasting peace for Ukraine.' The meeting of European leaders follows the US president's summit with Russian leader Vladimir Putin in Alaska on Friday. Mr Martin said it is 'essential that Ukraine is a full participant' in any discussions regarding its future. He said: 'I therefore welcome that President Zelensky will meet with President Trump in Washington tomorrow, together with other European leaders. Mr Martin said he stressed that international law and principles of independence, sovereignty and territorial integrity need to be respected for security in the region. 'It will be up to Ukraine to make decisions on its territory. International borders must not be changed by force. 'I fully agree that Ukraine needs strong, credible, long-term security guarantees. This will mean sustained support from Europe, the United States and other partners. 'Ireland stands ready to play our part. Earlier this year we committed to providing non-lethal military support to Ukraine and we will look to do more. 'At today's meeting, I also reiterated Ireland's readiness to contribute to any peacekeeping force that is in line with the UN Charter.' The Taoiseach said Ireland will also continue to support Ukraine's EU membership ambitions, adding that Russia 'cannot have a veto' on the matter. 'Our joint efforts for peace should be combined with firm and co-ordinated pressure on Russia to agree to a ceasefire and engage seriously with negotiations on a just and lasting peace. 'We agreed today that sanctions and wider economic measures will be reinforced if Russia does not stop the killing. 'The human dimension and accountability must also be at the centre of a just and lasting peace for Ukraine. 'Russia must urgently return Ukrainian children who they have abducted as well as prisoners of war and civilians being held unlawfully.'

Yahoo
23 minutes ago
- Yahoo
Volodymyr Zelenskyy to press for ceasefire at Donald Trump meeting
Volodymyr Zelenskyy will ask Donald Trump to increase pressure on Russia for a ceasefire in the Ukraine war at a White House meeting on Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio